NCT06918431 2026-03-17
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
Clinical Trials
8 trialsPhase 2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × asparaginase erwinia chrysanthemi recombinant × Clear all
NCT01451515 2022-06-28
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT01643408 2021-06-23
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Jazz Pharmaceuticals
Phase 2 Completed
NCT02718755 2018-06-26
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02419755 2018-03-07
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00186875 2017-07-28
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 2 Completed
NCT02150928 2015-05-13
An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)
Jazz Pharmaceuticals
Phase 2 Withdrawn
NCT00983138 2011-03-01
Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)
medac GmbH
Phase 2 Completed